Coffee Consumption and Prostate Cancer Risk: Results from National Health and Nutrition Examination Survey 1999-2010 and Mendelian Randomization Analyses

Abstract

The aim of this study was to examine the association between coffee and prostate cancer. Firstly, we conducted an observational study using data from National Health and Nutrition Examination Survey (NHANES) 1999-2010. Coffee intake was derived from 24 h dietary recalls. Weighted multivariable-adjusted logistic regression was applied to evaluate the association. Then, we performed Mendelian randomization (MR) to explore the possible causal effect of coffee on prostate cancer risk. Primary and secondary genetic instruments were obtained from genome-wide association studies among 375,833 and 91,462 individuals separately. Prostate cancer summary statistics were extracted from Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome (PRACTICAL) (79,194 cases and 61,112 controls) and FinnGen project (4754 cases and 63,465 controls). Inverse variance weighted (IVW) was the primary analytical method. Through selection, we enrolled 8336 individuals (weighted number = 58,796,070) for our observational study in NHANES. Results suggested that there was no association between coffee and prostate cancer. MR analyses with primary genetic instruments also did not support a causal association between coffee intake and prostate cancer risk, whether using summary data from PRACTICAL (IVW: OR 1.001, 95% CI 0.997-1.005) or FinnGen (IVW: OR 1.005, 95% CI 0.998-1.012). Similar results were observed when using secondary genetic instruments. Therefore, our study did not support a causal association between coffee intake and prostate cancer risk. Further studies with a larger sample size are needed to examine if an association exists by different coffee bean types, roasting procedures, and brewing methods.

Keywords: Mendelian randomization; National Health and Nutrition Examination Survey; PRACTICAL; coffee; prostate cancer.

Figure 1

Forest plot of MR using primary genetic instruments with prostate cancer outcome data from (A) PRACTICAL and (B) FinnGen. MR, Mendelian randomization; OR, odds ratio; CI, confidence interval; IVW, inverse variance weighted; PRACTICAL, Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome.

Figure 2

Forest plot of MR using secondary genetic instruments with prostate cancer outcome data from (A) PRACTICAL and (B) FinnGen. MR, Mendelian randomization; OR, odds ratio; CI, confidence interval; IVW, inverse variance weighted; PRACTICAL, Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome.